On November 21, the company hualan biological engineering, inc. (002007.SZ) announced that on November 21, 2024, its equity-participating company, Hualan Gene Engineering Co., Ltd. (hereinafter referred to as "Gene Company"), obtained the "Drug Registration Certificate" for Bevacizumab Injection issued by the State Food and Drug Administration.
Anbeiyu (Bevacizumab Injection), approved by the Gene Company, is mainly used to treat advanced, metastatic, or recurrent non-small cell lung cancer, metastatic colorectal cancer, recurrent glioblastoma, hepatocellular carcinoma, epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, cervical cancer. Originally developed by Roche, the company's Bevacizumab Injection has been approved for marketing by the National Medical Products Administration, considered equivalent to passing a biosimilar evaluation. Currently, manufacturers of Bevacizumab Injection include Roche, Qilu Pharmaceutical Co., Ltd., Innovent Bio Pharmaceuticals (Suzhou) Co., Ltd., among others. According to Minet data, the total sales of domestic Bevacizumab Injection in 2023 were approximately 10.7 billion yuan.
